An observational study in COVID-19, sponsored by Universidad de Antioquia. Status unknown at 1 site in Colombia. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by Universidad de Antioquia · Observational
Recent research evidence shows that levels of antibodies acquierd post vacunation against SARS-Cov-2 decrease over time as well as the efficacy to control the infection, additionally in a multicenter study carried out in 2020 were evidenced differences in the time it took to decrease the antibodies according to the type of vaccine, defined as mRNA or other types of vaccine.
In this study , the variation of the SARS-Cov-2 antibody levels in patients from Valle de Aburrá will be correlated according to the COVID-19 vaccine received.
After being informed about the study, all patients giving written informed consent will undergo a serial IgM -IgG COVID-19 antibodies blood test and SARS-Cov-2 PCR by nasopharingeal swab, that will be taken at the beginning of the study and mensually for two months.
During the study will be done an active search for SARS-CoV-2 infections in the vaccinated people cohort, and if it is posible to characterize the variant of SARS-CoV-2 in participants previously vaccinated against this pathogen.
The main objective of this study is to describe the pattern of antibodies blood test based in the type of vaccine and correlated the pattern of antibodies SARS-Cov-2 levels in a population of Valle de Aburrá.
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 200 is below the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →Universidad de Antioquia is the lead sponsor of 79 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
People with a fully vaccination scheme for COVID-19 according to the Ministerio de Salud y Protección Social de Colombia and patients diagnosed with SARS-CoV-2 infection in the last 60 days, without matter vaccination status against SARS-CoV-2.
Exclusion Criteria:
80 subjects with less than 4 months after being fully vaccinated against COVID-19
Diagnostic Test: Levels of IgG and IgM SARS-CoV-2 antibodies blood test. · Diagnostic Test: RT-PCR SARS-CoV-2 nasopharyngeal swab
80 subjects with more than 4 months after being fully vaccinated against COVID-19
Diagnostic Test: Levels of IgG and IgM SARS-CoV-2 antibodies blood test. · Diagnostic Test: RT-PCR SARS-CoV-2 nasopharyngeal swab
40 patients diagnostic of COVID-19
Diagnostic Test: Levels of IgG and IgM SARS-CoV-2 antibodies blood test. · Diagnostic Test: RT-PCR SARS-CoV-2 nasopharyngeal swab
0,1,2 months
0,1,2 months
IgG and IgM antibodies blood test levels generated by the different COVID-19 vaccines in people throughout the time of the study.
Time frame: Through study completion, an average of 2 months
Comparing immunoglobulins M and G levels in vaccinated patients against SARS-CoV-2 with RNA and non RNA vaccines.
Time frame: Through study completion, an average of 2 months
SARS-CoV-2 infections in vaccinated patients against COVID-19.
Time frame: Through study completion, an average of 2 months
Correlate through time immunoglobulins M and G levels in people vaccinated against COVID-19 and SARS-CoV-2 acute infected patients.
Time frame: Through study completion, an average of 2 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad de Antioquia